Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04887506 · ClinicalTrials.gov registry record · Phase 3

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, sponsored by Tavanta Therapeutics.

Completed
Registry status
Phase 3
Development phase
107
Enrollment target
20
Study locations

NCT04887506 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer that has completed, run by Tavanta Therapeutics. The registered enrollment target is 107 participants, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04887506, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, has completed, sponsored by Tavanta Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
107 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer Metastatic Prostate Cancer Metastatic Castration-Sensitive Prostate Cancer

Interventions

  • DRUG Prednisone
  • DRUG TAVT-45
  • DRUG Zytiga

Study Locations (20)

Other

  • Research Site - Brest
  • Research Site - Budapest
  • Research Site - Budapest
  • Research Site - Debrecen
  • Research Site - Bydgoszcz

California

  • Research Site - Los Angeles
  • Research Site - San Bernardino

Alabama

  • Research Site - Homewood

Arizona

  • Research Site - Tucson

Arkansas

  • Research Site - Little Rock

Colorado

  • Research Site - Denver

Florida

  • Research Site - Bradenton

Idaho

  • Research Site - Meridian

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2021-05-05
Est. Completion 2022-10-20
Phase Phase 3

Sponsor

Tavanta Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04887506

The ClinicalTrials.gov registry entry for NCT04887506 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (45% lower). The listed sponsor is Tavanta Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Prednisone is the first listed.

NCT04887506 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT04887506 about?

NCT04887506 is a clinical study titled "TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer". The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.

What is the current status of trial NCT04887506?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 107 participants. The study started on 2021-05-05. Estimated completion is 2022-10-20.

What conditions does trial NCT04887506 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer.

What interventions are being tested in trial NCT04887506?

The interventions under investigation include: Prednisone (DRUG), TAVT-45 (DRUG), Zytiga (DRUG).

Who is sponsoring clinical trial NCT04887506?

This trial is sponsored by Tavanta Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04887506 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Metastatic Prostate Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.